NA
INTS icon

NewEdge Advisors’s Intensity Therapeutics INTS Stock Holding History

NewEdge Advisors’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.75K Buy
1,148
+148
+15% +$1.21K ﹤0.01% 3498
2025
Q4 		$10.3K Buy
+1,000
New +$10.1K ﹤0.01% 3466

Other funds holding INTS

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.18B AUM 18.43% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

NewEdge Advisors's INTS Position: Q1 2026 in Review

NewEdge Advisors increased its Intensity Therapeutics (INTS) stake by 15% in Q1 2026, buying an estimated $1.21K and bringing the position to 1,148 shares worth $6.75K. The position accounts for ﹤0.01% of the portfolio, ranked #3498.

NewEdge Advisors first reported a position in INTS in Q4 2025 and has held it in 2 quarters since. The position peaked at $10.3K in Q4 2025. 13 funds tracked by Wall St. Rank hold INTS as of Q1 2026.

  • NewEdge Advisors held 1,148 shares of Intensity Therapeutics worth $6.75K as of Q1 2026.
  • NewEdge Advisors bought 148 Intensity Therapeutics shares in Q1 2026, an estimated $1.21K.
  • Intensity Therapeutics made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #3498 holding.
  • NewEdge Advisors first reported a position in Intensity Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • NewEdge Advisors's Intensity Therapeutics position peaked at $10.3K in Q4 2025.
  • 13 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.